AGT

Metagenomi Reports Business Updates and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, March 27, 2024
Research, Dicarboxylic acid, AAV, Enzyme, Development, Gene editing, CAST, Cardiovascular disease, Haemophilia, Vivisection, Patient, Primate, RNA, DNA, Wave 1, Sale, Metagenomics, G&A, IPO, Ultra, Doctor of Philosophy, Protein, MBA, Genome, SMART, Factor VIII, CRISPR, Amyloidosis, MGX, AGT, Liver, LNP, Ionis, PAM, Vaccine

EMERYVILLE, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today reported financial results for the full year ended December 31, 2023, and additional business updates.

Key Points: 
  • The aggregate gross proceeds to Metagenomi from the offering were approximately $93.75 million, before deducting underwriting discounts and commissions and offering expenses.
  • In addition, cash used to fund our operations was $91.4 million for the year ended December 31, 2023.
  • R&D Expenses: Research and development (R&D) expenses were $94.4 million for the full year ended December 31, 2023.
  • G&A Expenses: General and administrative (G&A) expenses were $28.8 million for the full year ended December 31, 2023.

Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension

Retrieved on: 
Sunday, April 7, 2024
Research, FDA, Clinical Trials, Cardiology, Biotechnology, Managed Care, Health, Pharmaceutical, Science, Blood pressure, Medication, Indapamide, Risk, Patient, Month, SBP, ABPM, American College, Olmesartan, Injection, Safety, RNA interference, Therapy, AGT, ACC, Amlodipine, Cardiomyopathy, Hypertension, Pharmaceutical industry

Zilebesiran is an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension with the potential for biannual dosing.

Key Points: 
  • Zilebesiran is an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension with the potential for biannual dosing.
  • The results were presented today as a late-breaking clinical trial at the 2024 American College of Cardiology (ACC) Annual Scientific Session.
  • The Company previously announced positive topline results from the KARDIA-2 study in March 2024.
  • “Although many effective oral treatments are available, a large proportion of patients with hypertension are not managed to guideline-recommended targets.

Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session

Retrieved on: 
Wednesday, March 20, 2024
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Managed Care, Health, Clinical Trials, Q&A, Medication, Webcast, Alnylam Pharmaceuticals, Angiotensin, American College, RNA interference, Therapy, AGT, ACC, Cardiomyopathy, Hypertension

The event will include presentations and a Q&A session with Alnylam management and Akshay Desai, M.D., Director of the Cardiomyopathy and Heart Failure Program, Brigham and Women’s Hospital.

Key Points: 
  • The event will include presentations and a Q&A session with Alnylam management and Akshay Desai, M.D., Director of the Cardiomyopathy and Heart Failure Program, Brigham and Women’s Hospital.
  • A replay of the call will be available two hours after the call and archived on the same webpage for six months.
  • A live audio webcast of the call will be available on the Investors section of the Company’s website at www.alnylam.com/events .
  • An archived webcast will be available on the Company’s website approximately two hours after the event.

Juniper Research Exposes the billion-dollar drain of Artificial Inflated Traffic (AIT) and SMS Trashing

Retrieved on: 
Tuesday, March 26, 2024
Research, Communication, OTT, AI, SMS, AIT, Fraud, AGT, Mobile phone

HONG KONG, March 26, 2024 /PRNewswire/ -- Juniper Research has unveiled a critical whitepaper detailing the pervasive and insidious issue of Artificially Inflated Traffic (AIT) and SMS Trashing within the business messaging sector. The comprehensive study was conducted in collaboration with VOX Solutions, with the aim to cast light on fraudulent activities that have led to increased operational costs for enterprises by charging for non-existent SMS traffic.

Key Points: 
  • Juniper Research and VOX Solutions have partnered to create a whitepaper which discusses the impact of Artificial Inflated Traffic and SMS This study provides crucial insights into the fraudulent practices threatening the integrity of business messaging.
  • HONG KONG, March 26, 2024 /PRNewswire/ -- Juniper Research has unveiled a critical whitepaper detailing the pervasive and insidious issue of Artificially Inflated Traffic (AIT) and SMS Trashing within the business messaging sector.
  • This new research reveals that in 2023, known AIT accounted for 18% of all international A2P SMS traffic, costing enterprises, including those of notable figures like Elon Musk, upwards of $60 million annually.
  • To discover more about the intricate dynamics of SMS fraud and the strategies to mitigate its impact, access the full whitepaper by Juniper Research: https://voxsolutions.co/the-impact-of-ait-sms-trashing-on-the-market-jun...

Juniper Research Exposes the billion-dollar drain of Artificial Inflated Traffic (AIT) and SMS Trashing

Retrieved on: 
Tuesday, March 26, 2024
Research, Communication, OTT, AI, SMS, AIT, Fraud, AGT, Mobile phone

HONG KONG, March 26, 2024 /PRNewswire/ -- Juniper Research has unveiled a critical whitepaper detailing the pervasive and insidious issue of Artificially Inflated Traffic (AIT) and SMS Trashing within the business messaging sector. The comprehensive study was conducted in collaboration with VOX Solutions, with the aim to cast light on fraudulent activities that have led to increased operational costs for enterprises by charging for non-existent SMS traffic.

Key Points: 
  • Juniper Research and VOX Solutions have partnered to create a whitepaper which discusses the impact of Artificial Inflated Traffic and SMS This study provides crucial insights into the fraudulent practices threatening the integrity of business messaging.
  • HONG KONG, March 26, 2024 /PRNewswire/ -- Juniper Research has unveiled a critical whitepaper detailing the pervasive and insidious issue of Artificially Inflated Traffic (AIT) and SMS Trashing within the business messaging sector.
  • This new research reveals that in 2023, known AIT accounted for 18% of all international A2P SMS traffic, costing enterprises, including those of notable figures like Elon Musk, upwards of $60 million annually.
  • To discover more about the intricate dynamics of SMS fraud and the strategies to mitigate its impact, access the full whitepaper by Juniper Research: https://voxsolutions.co/the-impact-of-ait-sms-trashing-on-the-market-jun...

Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives

Retrieved on: 
Tuesday, March 5, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Therapy, Blood pressure, DBP, Amlodipine, Roche, Month, Safety, Glomerular filtration rate, ABPM, Trial of the century, Cardiology, Indapamide, AGT, Hypertension, American College, SBP, EGFR, Patient, Angiotensin, DB, Alnylam Pharmaceuticals, Medication, RNA interference, Pharmaceutical industry

Zilebesiran demonstrated an encouraging safety and tolerability profile when added to these standard of care antihypertensives.

Key Points: 
  • Zilebesiran demonstrated an encouraging safety and tolerability profile when added to these standard of care antihypertensives.
  • “We are thrilled that a single dose of zilebesiran achieved clinically significant, additional reductions in systolic blood pressure when administered to patients who are not adequately controlled with commonly prescribed antihypertensives,” said Simon Fox, Ph.D., Vice President, Zilebesiran Program Lead at Alnylam.
  • “These KARDIA-2 results, showing durable additional levels of blood pressure reduction on top of what is achieved by standard of care first-line antihypertensives with an encouraging safety profile, reinforce our confidence in zilebesiran’s differentiated profile.
  • The primary endpoint is the change from baseline in mean SBP at Month 3, assessed by 24-hour ABPM.

Acacia Research Announces Licensing and Settlement Agreements Related to WiFi-6 Patents

Retrieved on: 
Wednesday, February 7, 2024
Professional Services, Technology, Legal, Mobile, Wireless, Telecommunications, Carriers and Services, Patent, AGT, Acacia Research, ACTG, Pharmaceutical industry

Acacia Research Corporation (Nasdaq: ACTG) today announced an agreement related to its intellectual property business.

Key Points: 
  • Acacia Research Corporation (Nasdaq: ACTG) today announced an agreement related to its intellectual property business.
  • Atlas Global Technologies LLC (“AGT”), a subsidiary of Acacia Research Group LLC (the patent licensing business of Acacia Research Corporation), entered into licensing and settlement agreements relating to its WiFi-6 patent portfolio during the fourth quarter of 2023, with aggregate payments under such agreements totaling more than $81 million.
  • The details of such license and settlement agreements, including the parties and individual payment amounts, are confidential pursuant to those agreements.
  • The amount received by AGT will be net of customary legal fees and other expenses.

Macau LRT Barra Extension Line Begins Commercial Operations on December 8

Retrieved on: 
Friday, December 8, 2023
Economic development, Automated guideway transit, Airport, Extension, Seac Pai Van, Macau Peninsula, AGT, Macau Light Rapid Transit, Tourism, Taipa line, Taipa, Transport, MHI, Population growth, CO2, Development, LRT, Casino

The Barra Extension (1 station expansion, 3.2km) project was constructed by laying a dedicated Macau LRT lane within an existing bridge, connecting the Macau Peninsula on the opposite bank to the Taipa Line (11 stations, 9.3 km), which MHI delivered in 2019.

Key Points: 
  • The Barra Extension (1 station expansion, 3.2km) project was constructed by laying a dedicated Macau LRT lane within an existing bridge, connecting the Macau Peninsula on the opposite bank to the Taipa Line (11 stations, 9.3 km), which MHI delivered in 2019.
  • The Macau LRT is a key transportation infrastructure connecting the airport and ferry terminals, which are tourist access points, with resort hotels and residential areas.
  • The other line is for the Hengqin Extension (2 station expansions, 2.2km) running to Hengqin in China from the opposite bank in Macau.
  • (3) For details of MHI Receives Contract for Extensions to the Macau LRT Network Using an AGT System, see the following press release: https://www.mhi.com/news/22041402.html

Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk

Retrieved on: 
Saturday, November 11, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, AGT, Blood pressure, Hypertension, Safety, Month, RNA interference, AHA, Patient, American Heart Association, ABPM, Therapy, University, SBP, Female, Medication, Pharmaceutical industry

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive results from the KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of patients with hypertension and high cardiovascular risk.

Key Points: 
  • Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive results from the KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of patients with hypertension and high cardiovascular risk.
  • The study results were presented during the American Heart Association (AHA) Scientific Sessions being held in Philadelphia, Pennsylvania from November 11-13, 2023.
  • The Company previously announced positive topline results from the KARDIA-1 study in September 2023.
  • The study also met key secondary endpoints across all doses, including demonstration of durable efficacy out to 6 months.

Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular Risk

Retrieved on: 
Thursday, September 7, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Cardiology, Blood pressure, SBP, University, Therapy, American Heart Association, Serum, Roche, COVID-19, AGT, ISR, Medicine, Month, Arthralgia, Medication, Hypertension, Death, Injection site reaction, DB, ABPM, Arrest, Patient, Risk, Mercury (element), Alnylam Pharmaceuticals, RNA interference, Upper respiratory tract infection, Headache, Hyperkalemia, Safety, Pharmaceutical industry

The study results indicate zilebesiran was associated with dose-dependent, potent and durable knockdown of serum AGT levels through Month 6.

Key Points: 
  • The study results indicate zilebesiran was associated with dose-dependent, potent and durable knockdown of serum AGT levels through Month 6.
  • Zilebesiran also demonstrated an encouraging safety and tolerability profile that the company believes supports continued development.
  • These findings of robust and tonic blood pressure control will help determine the optimal dose and regimen of zilebesiran for future studies.
  • “Hypertension is a growing global health crisis responsible for around 10 million deaths worldwide each year.